WSJ article highlights known debates on safety of Zoetis’ Librela, says BofA

BofA notes that The Wall Street Journal published an article discussing the safety profile for Librela and Solensia, Zoetis’ first-in-class monoclonal antibodies, or mAbs, for the treatment of osteoarthritis pain in pets. The article “largely restated what was already known about the situation,” that the drug has been widely used and there have been adverse events, but they’re relatively rare and do not appear to be directly attributable to the drug or its active ingredients, said the analyst, who also noted that many of the vets cited in this morning’s article continue to prescribe Librela. The firm, which remains constructive on Zoetis, particularly after the recent selloff in shares, maintains a Buy rating and $205 price target on the stock.